Janus Henderson Group
TBPH icon

Janus Henderson Group’s Theravance Biopharma TBPH Stock Holding History

Janus Henderson Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.15M Sell
378,978
-21,518
-5% -$381K ﹤0.01% 898
2025
Q4 		$7.49M Buy
400,496
+273,288
+215% +$4.53M ﹤0.01% 811
2025
Q3 		$1.86M Buy
+127,208
New +$1.61M ﹤0.01% 1362
2025
Q1 		– Sell
-24,666
Closed -$232K – 2547
2024
Q4 		$232K Hold
24,666
– – ﹤0.01% 2364
2024
Q3 		$199K Hold
24,666
– – ﹤0.01% 2432
2024
Q2 		$209K Sell
24,666
-237
-1% -$2.14K ﹤0.01% 2375
2024
Q1 		$223K Buy
24,903
+6
+0% +$56 ﹤0.01% 2373
2023
Q4 		$280K Sell
24,897
-40
-0.2% -$403 ﹤0.01% 2265
2023
Q3 		$215K Sell
24,937
-51
-0.2% -$492 ﹤0.01% 2345
2023
Q2 		$259K Sell
24,988
-55
-0.2% -$607 ﹤0.01% 2333
2023
Q1 		$272K Buy
25,043
+14,055
+128% +$149K ﹤0.01% 2328
2022
Q4 		$123K Sell
10,988
-10,990
-50% -$116K ﹤0.01% 2297
2022
Q3 		$224K Buy
21,978
+10,904
+98% +$102K ﹤0.01% 2355
2022
Q2 		$100K Buy
11,074
+78
+0.7% +$719 ﹤0.01% 2472
2022
Q1 		$105K Sell
10,996
-3
-0% -$29 ﹤0.01% 2553
2021
Q4 		$122K Buy
+10,999
New +$95.9K ﹤0.01% 2485

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's TBPH Position: Q1 2026 in Review

Janus Henderson Group reduced its Theravance Biopharma (TBPH) stake by 5.4% in Q1 2026, selling an estimated $381K and leaving 378,978 shares worth $6.15M. The position accounts for ﹤0.01% of the portfolio, ranked #898.

Janus Henderson Group first reported a position in TBPH in Q4 2021 and has held it in 16 quarters since. The position peaked at $7.49M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Janus Henderson Group held 378,978 shares of Theravance Biopharma worth $6.15M as of Q1 2026.
  • Janus Henderson Group sold 21,518 Theravance Biopharma shares in Q1 2026, an estimated $381K.
  • Theravance Biopharma made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #898 holding.
  • Janus Henderson Group first reported a position in Theravance Biopharma in Q4 2021 and has held it in 16 quarters since.
  • Janus Henderson Group's Theravance Biopharma position peaked at $7.49M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.